@article{fe4d7129f4d94965a867ea6f38b43c11,
title = "Food Allergy and Eosinophilic Gastrointestinal Diseases—The Next 10 Years",
abstract = "The first report of food allergy desensitization was in 1908, at least a few years before the first published description of a diagnostic test for food allergy. It has taken almost 100 years for food allergy to move from passive management of avoidance to a more proactive approach including prevention and treatment. In parallel, this has been matched by recognition of eosinophil gastrointestinal diseases, which were first described in the 1980s (although eosinophilic esophagitis was itself described in 1978). As we celebrate 10 years of The Journal of Allergy and Clinical Immunology: In Practice, we take the opportunity to look into the future and speculate how our practice may develop over the next decade.",
keywords = "Anaphylaxis, Desensitization, Eosinophilic gastrointestinal disease, Food allergy, Outcomes",
author = "Turner, {Paul J.} and Tang, {Mimi L.K.} and Wood, {Robert A.}",
note = "Funding Information: Conflicts of interest: P.J. Turner declares research grants from UK Medical Research Council, the National Institute for Health and Care Research–Imperial Biomedical Research Centre, the JM Charitable Foundation, and the UK Food Standards Agency; and personal fees from the UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, and Novartis. M.L.K. Tang declares consultant fees from Pfizer and Novartis; inventorship on patents covering probiotic and peanut oral immunotherapy; past employee and share interest/options in Prota Therapeutics; membership of the Medical Advisory Board of Anaphylaxis & Anaphylaxis Australia and past membership of the Board of Directors of the World Allergy Organization (ended in 2019); membership of expert committees of the American Academy of Allergy Asthma and Immunology, Asia Pacific Association of Allergy Asthma and Clinical Immunology, Australasian Society of Clinical Immunology and Allergy, and world Health Organization; and past membership of the International Union of Immunological Societies (ended in 2019). R.A. Wood receives research support from the National Institute of Allergy and Infectious Diseases, Aimmune, Astellas, DBV, Food Allergy Research and Education, Genentech, HAL-Allergy, Novartis, Regeneron, and Siolta; and royalties from UpToDate. Funding Information: Conflicts of interest: P.J. Turner declares research grants from UK Medical Research Council, the National Institute for Health and Care Research–Imperial Biomedical Research Centre, the JM Charitable Foundation, and the UK Food Standards Agency; and personal fees from the UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics, and Novartis. M.L.K. Tang declares consultant fees from Pfizer and Novartis; inventorship on patents covering probiotic and peanut oral immunotherapy; past employee and share interest/options in Prota Therapeutics; membership of the Medical Advisory Board of Anaphylaxis & Anaphylaxis Australia and past membership of the Board of Directors of the World Allergy Organization (ended in 2019); membership of expert committees of the American Academy of Allergy Asthma and Immunology, Asia Pacific Association of Allergy Asthma and Clinical Immunology, Australasian Society of Clinical Immunology and Allergy, and world Health Organization; and past membership of the International Union of Immunological Societies (ended in 2019). R.A. Wood receives research support from the National Institute of Allergy and Infectious Diseases, Aimmune, Astellas, DBV, Food Allergy Research and Education, Genentech, HAL-Allergy, Novartis, Regeneron, and Siolta; and royalties from UpToDate. Publisher Copyright: {\textcopyright} 2022 American Academy of Allergy, Asthma & Immunology",
year = "2023",
month = jan,
doi = "10.1016/j.jaip.2022.10.038",
language = "English (US)",
volume = "11",
pages = "72--78",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "1",
}